YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

Phase 2 Terminated Astellas Pharma Inc Astellas Pharma US, Inc. · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Timeline

Start: —
Primary completion: —
Completion: 2004-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NEBENTAN	Small molecule	—	—

YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

Summary

Timeline

Drugs

Indications